Tiziana Life Sciences
  • Our Company
    • Our Company
    • About us
    • Our Team
  • Technology
  • Pipeline
    • Intranasal Foralumab
      • Secondary Progressive Multiple Sclerosis
      • Alzheimer’s Disease
      • Other Indications
    • Anti IL-6R (TZLS-501)
    • Milciclib (TZLS-201)
  • Investors, News & Media
    • News
    • Media
    • Publications
    • Investors
  • Contact
Select Page
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

by Paul | 21 February 2025 | News

NEW YORK, February 21, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...

Recent Posts

  • Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
  • Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
  • Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
  • Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
  • Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Recent Comments

No comments to show.

Tiziana Life Sciences, Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda  |  info@tizianalifesciences.com   |  +44 (0) 207 495 2379

  • Follow
  • Follow

© Tiziana Life Sciences 2026  |   Legal  |  Privacy Policy

NASDAQ: TLSA